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The existence of the teneurin C-terminal associated peptides (TCAP) was reported in
2004 after screening a rainbow trout hypothalamic cDNA for corticotropin-releasing factor
(CRF)-related homologs. In vertebrates, there are four TCAP paralogs, where each peptide
is associated with a teneurin transmembrane protein. The TCAPs are 40 or 41 amino
acids in length and possess less than 20% residue identity with the CRF family of
paralogs. Orthologs of TCAP are found in all metazoans with the possible exception of
poriferans and cnidarians. Recent evidence indicates that TCAP and the teneurins may
have been introduced into the Metazoa via horizontal gene transfer from prokaryotes
into a basal protistan. Thus, the origin of the TCAPs likely predated that of the CRF
family. In the mammalian brain, TCAP-1 is transcribed independently from teneurin-1.
Moreover, TCAP-1 acts on neurons by a CRF-receptor independent signal transduction
pathway to regulate cellular cytoskeletal function to stimulate cell activity. Administration
of synthetic TCAP-1 to rodents inhibits a number of CRF- and stress-associated behaviors
via a hypothalamic–pituitary–adrenal (HPA) axis-independent mechanism.
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INTRODUCTION
Corticotropin-releasing factor (CRF) is part of an evolutionary
conserved peptide family integral to the regulation of stress-
associated behavior and physiology in metazoans. The long
period of time during which CRF-like peptides have persisted
suggests that the CRF response has been evolutionarily advanta-
geous. Early-evolving gene systems integral to the survival of an
organism are evolutionarily selected for, and because of this, may
give rise to additional paralogous lineages via gene, genomic, and
chromosomal duplication events. In addition, such early evolving
systems will likely become associated with newer evolving molec-
ular and physiological systems. Thus, because of the evolutionary
age of the CRF system, it is likely that it is modulated, in turn, by
even earlier evolving systems.
One such candidate for an early evolving CRF-modulatory sys-
tem may be represented by TCAP-1, a member of the teneurin
C-terminal-associated peptides family. Highly conserved in all
metazoans, TCAP-1 is active in the regulation of metabolism,
stress, and reproduction and significantly inhibits a number of
CRF-induced stress responses. Although TCAP was originally
identified in a rainbow trout cDNA library screen for potential
CRF homologs and share a number of structural similarities with
the CRF family of peptides, they have less than 20% sequence
similarity to the CRF family (Qian et al., 2004; Lovejoy et al.,
2006). In situ experiments in Sprague-Dawley rats show that
TCAP is highly expressed in all hippocampal subregions, cen-
tral amygdala (CeA), basolateral amygdala (BLA), and various
hypothalamic nuclei regions that are known to express CRF
receptors (Wang et al., 2005). The TCAP-1 peptide also blocks
both CRF-induced stress behaviors and c-fos activation within
brain areas known to modulate behavioral responses to stress in
Wistar rats (Tan et al., 2009). Recent studies show that TCAP
exerts its neuromodulatory role on CRF elements independent
of the hypothalamic–pituitary–adrenal (HPA) axis, harboring the
idea that several accessory pathways may have evolved alongside
the HPA axis-mediated signaling pathway.
CRF EVOLUTION AND PHYSIOLOGY
In vertebrates (Mammalia, Amphibia, Actinoptergyii, and
Chondrichthyes), the CRF family consists of four paralogous pep-
tides that are the result of two rounds of genome duplications
in early evolution and has been previously described in detail
(Lovejoy and Balment, 1999; Lovejoy and Jahan, 2006) (Figure 1).
Orthologs of CRF in invertebrates occur as the diuretic hormones
in arthropods, and diuretic hormone-like peptide in tunicates.
These findings indicate that only a single CRF peptide was present
in the genome of an ancestral protochordate. The first of the
genome duplications led to the formation of two CRF-related
peptides. After subsequent selection, both lineages were retained
but modified during the accrual of mutations leading to a mod-
ified amino acid sequence. One peptide shares sequence simi-
larities to both CRF and urotensin-1 (urocortin in mammals;
Vaughan et al., 1995; Donaldson et al., 1996), whereas the second
peptide possesses both urocortin 2 and 3 characteristics (Lovejoy
and Jahan, 2006). The second genome duplication led to the for-
mation of the four peptides that are found in extant vertebrates
(Lewis et al., 2001; Reyes et al., 2001). However, the presence of
CRF orthologs in arthropods indicates that the earliest CRF-like
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FIGURE 1 | Comparison of the CRF peptides family in chordates by
genome duplication. Two rounds of genome duplications early in chordate
ancestry gave rise to the four paralogous CRF related peptides.
Abbreviations: DH, diuretic hormone; DH/CRF, diuretic
hormone/corticotrophin releasing factor like peptide; CRF, corticotrophin
releasing factor; UCN, urocortin; UCN2, urocortin 2; UCN3 urocortin 3; gd,
genome duplication event.
peptides existed before the bifurcation of deuterostome and pro-
tostome animals (Lovejoy and Balment, 1999; Lovejoy and Jahan,
2006). Research in the last few decades has provided a basis for
understanding the regulation of stress and metabolism by CRF.
Currently, it is understood that in vertebrates, CRF activates the
stress response through the HPA axis. It is also through this path-
way that CRF is regulated by modulatory components of the
central nervous system.
The ancient evolution of CRF and CRF-like peptides indi-
cates that there is functional necessity of the actions of CRF on
regulatory mechanisms in physiology. In many species, humans
included, CRF induces behaviors and physiological adaptations
that endeavor to cope with environmental stressors. Stressors that
are associated with new environments, for example, generally
bring about behaviors of increased arousal and decreased food
intake. Changes in behaviors and physiology that are induced by
CRF aremediated by interactions of CRF/Ucnwith both the CRF1
and CRF2 receptors. Urocortin-2 and -3 mediate their functions
through a separate CRF2 receptor (Hauger et al., 2006).
In numerous vertebrates including Osteichthyes, Amphibia,
Reptilia, Avia, and Mammalia species, exposure to stress leads to
activation of the hypothalamic–pituitary–adrenocortical (HPA)
axis (Barsyte et al., 1999; Lovejoy and Balment, 1999; Lovejoy
and Jahan, 2006; Denver, 2009; Lovejoy, 2009). The HPA axis is a
neuroendocrine feedback system that is activated when afferents
from the sensory system and brainstem signal to the paraven-
tricular nucleus (PVN) to secrete CRF and arginine vasopressin
(AVP) hormones into the hypophyseal portal system (Tsigos and
Chrousos, 2002; Ulrich-Lai and Herman, 2009). Upon reaching
the anterior pituitary, CRF stimulates the corticotropes to secrete
adrenocorticotropic hormone (ACTH) into the systemic circula-
tion (Tsigos and Chrousos, 2002; Denver, 2009). This hormone
in turn acts on the inner adrenal cortex to synthesize and release
glucocorticoids, such as cortisol (Denver, 2009; Ulrich-Lai and
Herman, 2009). Circulating glucocorticoids induce a multitude
of different responses which all act to promote energy mobi-
lization; these include gluconeogenesis in the liver, liberation of
amino acids, inhibition of glucose uptake intomuscle and adipose
tissue, increased lipolysis and suppression of immune and repro-
ductive functions (Ulrich-Lai and Herman, 2009). Regulation
of the system occurs through negative feedback of glucocorti-
coids at the hypothalamus and anterior pituitary, inhibiting the
release of CRF and ACTH respectively; in addition, the action
of glucocorticoids on neuronal inputs to the PVN restricts acti-
vation of the HPA axis (Tsigos and Chrousos, 2002; Denver,
2009). However, the HPA system, as it is understood in verte-
brates, does not appear to be present in non-vertebrates (Lovejoy,
2009). Thus, given the evolutionary age of CRF-like peptides, it
has become well ensconced in numerous physiological processes
predating the HPA axis. However, CRF itself has a number of
non-HPA associated functions including feeding, diuresis, meta-
morphosis, locomotion, and vocalization (Lovejoy and Balment,
1999). These regulatory actions may have evolved to accompany
stress regulation. Given the widespread actions of the CRF fam-
ily of peptides, evolutionarily older physiological systems may be
working alongside the CRF lineage or interacting with elements
of the CRF lineage in a neuromodulatory manner in complex
organisms.
TENEURIN AND THE TENEURIN C-TERMINAL ASSOCIATED
PEPTIDES (TCAP)
The teneurins are a family of four type-II transmembrane pro-
teins that are critical for morphogenesis and pattern formation
in metazoans (Wang et al., 2005; Lovejoy et al., 2006, 2009;
Tucker et al., 2007; Young and Leamey, 2009). Originally discov-
ered in Drosophila, teneurins were later discovered in vertebrates
to have four paralogs (teneurin-1 to -4) (Kenzelmann et al.,
2007). Vertebrate teneurins are predominately expressed in the
nervous system and have been implicated in neural development
and maintenance (Lovejoy et al., 2006; Kenzelmann et al., 2007).
They are typically about 2800 amino acids long with a structure
that is highly conserved (Tucker et al., 2007). At the end of the
C-terminus of teneurin-1 to -4 is a cleavable bioactive peptide
termed the teneurin C-terminal-associated peptide (TCAP)-1
to -4. Recent studies, however, indicate that TCAP-1 is indepen-
dently transcribed from teneurin-1, thus providing evidence for
the independence of TCAPs from teneurins (Chand et al., 2012a).
Initial attempts to identify paralogous genes to the CRF family
led to the discovery of this TCAP family (Qian et al., 2004). It was
first discovered in a screening of the hypothalamic cDNA library
of rainbow trout using a hamster urocortin probe (Barsyte et al.,
1999; Qian et al., 2004). Sequence analyses revealed a putative
peptide sequence on the 3′ region of teneurin-3 in trout and this
peptide sequence was termed TCAP-3, by virtue of its association
with teneurin-3 (Qian et al., 2004). Further analyses led to the
discovery of the 3 other TCAP peptides on teneurins-1, -2, and -4
(Wang et al., 2005). The TCAP family is ubiquitously expressed
among all metazoan species (Lovejoy et al., 2006; Tucker et al.,
2012). The four vertebrate TCAP paralogs show about 80% iden-
tity with each other amongst metazoan species (Lovejoy et al.,
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2006, 2009). This high level of conservation indicates that this
family of peptides evolved before the protostome-deuterostome
divergence and that its role implicates a functional necessity for
organisms. The teneurin-TCAP system likely evolved by horizon-
tal gene transfer from a prokaryote gene to a choanoflagellate
(Zhang et al., 2012), where subsequently this gene integrated
within the choanoflagellate genome and was passed into subse-
quentmetazoan speciation (Tucker et al., 2012; Chand et al., 2013;
Tucker, 2013). Moreover, there is 13–30% similarity with vari-
ous peptides and the CRF family of peptides (Wang et al., 2005;
Lovejoy et al., 2006) (Figure 2). This level of sequence similarity,
along with the peptide and mRNA size suggests that there may
be a common origin in evolutionary history with the CRF pep-
tides, although the evolutionary relationship between the lineages
is not understood (Chand et al., 2013; de Lannoy and Lovejoy,
in press).
The TCAP family of peptides all have characteristics of a cleav-
able bioactive peptide; a cleavage motif on the N-terminus and
an amidation motif on the C-terminus. The TCAP-1, -2, and -
4 peptides are 41-amino residues in length and TCAP-3 is 40
amino residues in length (Lovejoy et al., 2006). Of the four,
mouse TCAP-1 is the only peptide in the family confirmed to
be expressed as a separate transcript from the teneurin gene
in adults, although this may be the case for mouse TCAP-3
as well. Thus, in our model of TCAP release, we assume that
TCAP-2 and -4 are released by ectodomain cleavage, whereas
TCAPs -1 and -3 may be released by ectodomain cleavage and
by independent transcription, translation, and subsequent release
via cytosolic processes. Studies in zebrafish, chick, and rodents
indicate that although expressed throughout the brain, TCAP-1 is
particularly concentrated in the limbic regions including the hip-
pocampus, hypothalamus, and amygdala (Wang et al., 2005; Tan
et al., 2009, 2011). It is in the rat hippocampus and amygdala that
TCAP-1 has been shown to exert its neuromodulatory effects on
behavior and stress.
NEUROMODULATION OF CRF-INDUCED BEHAVIOR BY
TCAP-1
Gene expression studies on mouse brain revealed that TCAP-
1 (as part of the teneurin-1 gene) was expressed mainly in
the limbic system, hypothalamus and cerebellum (Wang et al.,
2005), suggesting these areas as focal points of TCAP-1 action.
FIGURE 2 | Comparison of the primary structure between the TCAP
and CRF families of peptides. Amino acid identity among CRF paralogs
are shown as dark gray, and continued among TCAP peptides where they
match. Conservative homologous substitutions are shown in light gray.
Note that the identity among TCAP peptides is much greater than that of
CRF peptides.
However, like other neuromodulatory peptide systems, behav-
ioral studies in rodents indicate that TCAP-1 has differen-
tial effects on anxiety depending upon the test, the treatment
regimen, and perhaps even the baseline anxiety level of rats
(Rotzinger et al., 2010). Acute administration of synthetic TCAP-
1 into the BLA significantly increases the acoustic startle response
in low-anxiety rats and decreases the response in high-anxiety
rats (Wang et al., 2005). Repeated administration of TCAP-1
at picomole concentrations into the lateral ventricles decreased
acoustic startle in all rats. A 50% decrease in the acoustic
startle response was apparent 15 days after the last TCAP-1
treatment (Wang et al., 2005). Moreover, using the same reg-
imen, TCAP-1 treatment completely ablated the CRF-induced
increase in the acoustic startle response (Tan et al., 2008). In
contrast, the same pre-treatment potentiated the effects of a
CRF ICV challenge in the elevated plus maze and open field
tests, where, upon CRF challenge, rats showed decreased open
arm entries in the elevated plus maze, and decreased locomo-
tion, as well as time, entries and distance traveled in the center
zone of the open field (Tan et al., 2008). However, IV injec-
tions of TCAP-1 resulted in differential behaviors in response
to an IV or ICV CRF challenge (Al Chawaf et al., 2007b).
Overall, rats treated with repeated IV doses of TCAP-1, fol-
lowed by an acute ICV CRF challenge were less anxious than
rats given an injection of CRF via the IV route (Al Chawaf
et al., 2007b). Again, these behavioral effects only occurred
upon co-administration with CRF; TCAP alone had little effect
on behavior, further indicating that this peptide plays a neu-
romodulatory role. This stress-mediated action of TCAP-1 is
further reflected by studies using a cocaine reinstatement model
(Kupferschmidt et al., 2010). Using the number of active lever
responses as tests for reinstatement of cocaine seeking, prior
TCAP-1 treatment in rodents resulted in fewer lever responses
after a CRF injection. However, TCAP-1 pre-treatment did not
modulate reinstatement by footshock stress, or cocaine-induced
reinstatement.
The difference in effects of TCAP-1 on IV- vs. ICV- injected
CRF in rats also suggests that TCAP-1 may be involved in the
feedback of glucocorticoids to the brain. A previous study in
mice (Martins et al., 1996) found that ICV-administered CRF
induces its effects by targeting sites in the CNS as well as periph-
eral sites along the HPA axis. However, IV-administered CRF
does not cross the blood–brain barrier and thus will only acti-
vate the HPA axis at the level of the pituitary and adrenal gland
(Martins et al., 1996). Thus, the difference in TCAP-1 effects on
ICV- and IV-administered CRFmay be due to amodulatory effect
of the glucocorticoid receptors or signaling in limbic regions by
TCAP-1. In particular, TCAP-1 may be acting on the hippocam-
pus and amygdala to change the sensitivity of the glucocorticoid
feedback on the PVN CRF secretion.
Further studies indicated the action of TCAP-1 occurs at a
pre-transcription and cellular activation level. TCAP-1 atten-
uates expression of CRF-induced c-fos in the amygdala (Tan
et al., 2009). Rats pre-treated with TCAP-1 showed lower c-Fos
immunoreactivity in the amygdala, medial prefrontal cortex, hip-
pocampus, and the dorsal raphe nucleus upon ICV CRF injec-
tions. Activation of CRF promotes c-fos synthesis and expression
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through a PKA/cAMP/CamKII pathway that leads to CREB
phosphorylation. Phosphorylated CREB then regulates c-fos gene
transcription by binding to response elements CRE and AP-1
(Kovacs, 1998). Similarly to CRF, TCAP-1 leads to cAMP accu-
mulation in vitro (Wang et al., 2005). Studies on Gn11 mouse
immortalized cell lines show that TCAP-1 has a biphasic effect
on cAMP such that low concentrations of TCAP-1 increased
cAMP, and high concentrations decreased cAMP levels (Wang
et al., 2005). Moreover, a CRF1 receptor antagonist addition failed
to block the TCAP-1-induced increase in cAMP suggesting the
presence of independent signaling pathways.
Administration of TCAP alone had a minor effect on c-fos
activation in vivo in rats. However, TCAP administration after
concomitant CRF administration produced significant behavioral
changes (Tan et al., 2009). This strongly suggests that TCAP
plays a neuromodulatory role on elements of CRF signaling sys-
tems. Evidence shows that glucocorticoids inhibit AP-1 and CRE
responses (Kovacs, 1998). Thus, TCAP could regulate elements
of CRF signaling through modulation of CRE and AP-1 activ-
ity. In addition, TCAP could inhibit CRF-induced c-fos through
inhibition of CRF expression itself, as the promoter of the CRF
gene contains a CRE (Hauger et al., 2006). Using luciferase
reporter assays, we found that TCAP administration decreases
AP-1 reporter activity in an immortalized N3 hypothalamic cell
line (Nock et al., unpublished observations). Thus, TCAP’s abil-
ity to attenuate CRF induced c-fos activation in vivo may be,
in part, through interactions with the AP-1 response element.
However, AP-1 is regulated by numerous elements, and TCAP-1
may regulate AP-1 activity by a CRF-independent mechanism.
In vitro, TCAP-1 administration did not alter CRF-induced
cAMP increases in the hypothalamic cell line Gn11 (Wang et al.,
2005), nor CRF-induced CRE activation in human embryonic
kidney cells transfected with CRF1 and CRF2 receptors. In vitro,
TCAP-1 does not modulate cellular distribution or total protein
of CRF1, or the GC receptors GR and MR in mouse embry-
onic hippocampal E14 cells. Administration of TCAP-1 also did
not modulate the phosphorylation of a CRF1 downstream tran-
scription factor CREB. Repeated daily TCAP-1 administration
in mice did not affect basal non-stressed HPA activity based on
serum cortisol and ACTH levels. From these studies, it is appar-
ent that under basal non-stressed conditions, TCAP-1 does not
interact directly with HPA regulatory pathways involving CRF or
GC receptors (De Almeida et al., unpublished studies).
The lack of direct interaction of TCAP-1 on CRF signal
transduction systems led us to investigate alternative explana-
tions for its mechanism. The similarity of the TCAP-1 primary
structure to CRF and related peptides had led us to postulate
that the peptide activated a G-protein coupled receptor (GPCR)
similar to the family of GPCRs related to the CRF receptors.
However,in vitro screening of most of the receptors in this fam-
ily did not show any significant binding or activation (Lovejoy,
unpublished studies). However, gene microarray profiling indi-
cated a similarity to neurotrophic factor activation and a rela-
tionship with the dystroglycan complex (Chand et al., 2012b).
Subsequent studies confirmed this relationship, thus TCAP-1
may be the first identified soluble ligand for the dystroglycan
complex. The dystroglycan complex is hypothesized to be inte-
gral to the intracellular signaling of extracellular TCAP-1 due
to a strong co-localization of TCAP-1 with β-dystroglycan, the
plasma membrane bound subunit of the dystroglycan complex
(Chand et al., 2012b). In essence, TCAP-1 mediates cytoskele-
tal re-organization in E14 cells by binding to the dystroglycan
complex which then signals through a MEK- ERK1/2-dependent
phosphorylation of stathmin and filamin A. This leads to f-
actin polymerization, increased tubulin immunoreactivity, and
increased filopodia development (Chand et al., 2012b). The
ERK1/2 pathway is the proposed mechanism through which
TCAP-1 modulates neurite and dendrite morphology in immor-
talized mouse hypothalamic cell lines, primary hippocampal cul-
tures (Al Chawaf et al., 2007a), and Golgi-stained rat brains (Tan
et al., 2011).
Within multiple areas of the mouse brain, CRF induces stress-
related cytoskeletal changes. CRF1 activation in the CA3 mediates
dendritic retraction by inducing destabilization of f-actin and
the cell adhesion molecule nectin-3 (Chen et al., 2008; Wang
et al., 2011). Activation of CRF1 in the locus coeruleus (LC)
also mediates outgrowth of neuronal processes through the Rho
GTPase Rac1 (Swinny and Valentino, 2006). In the hippocam-
pus, this Rac1-dependent outgrowth of neuronal processes is
counteracted by RhoA inhibition on dendritic spine formation
and branching. Thus, TCAP-1 may exert its CRF modulating
effects through countering CRF1 mediated changes in cytoskeletal
re-organization-like synaptic plasticity within stress modulating
brain areas that express both CRF1 and TCAP-1.
CONCLUSION
Current data suggests that TCAP-1 acts as a separate and distinct
peptide modulating system, which is involved in cytoskeletal-
associated synaptic plasticity. From an evolutionary perspective,
it is perhaps not surprising that TCAP-1 acts independently of
CRF signaling. The teneurins and TCAP evolved early in meta-
zoan history, whereas the CRF family of peptides and their role
in integrating energy metabolism and the perception of stressors
evolved later after evolution of vertebrates (Lovejoy and Jahan,
2006; Lovejoy, 2009). Moreover, the later evolution of the HPA
axis in stress signaling and the independence of TCAP-1 neur-
modulatory actions from the HPA axis further support a possible
parallel evolution. The TCAP-1 peptide acts on the dystrogly-
can complex in order to signal intracellularly. This signaling may
be downstream of other effectors from the CRF signaling path-
way downstream of the CRF1 receptor. The observed TCAP-1
modulatory effects on CRF behaviors may then be mediated
through TCAP-1 specific signaling that oppose CRF mediated
effects on cellular cytoskeletal organization within brain areas that
co-express TCAP-1 and CRF. This in turn manifests into mod-
ulation of CRF-mediated stress behaviors in brain regions that
co-express CRF and TCAP-1.
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